



## GE Healthcare – Sensitivity and Specificity Factsheet

Among the questions radiologists have to answer every day there are three main categories that frequently occur:

- **Sensitivity:** How good is a test at finding what you're looking for?
- **Specificity:** If a test does find something suspicious, how good is it at empowering medical professionals to make a diagnosis?
- **Negative Predictive Value (NPV):** If a test shows nothing, how confident can one be in telling the patient that there is **really** nothing to worry about?

Improvements in any of these three categories would be important, but improvements in all three is a real breakthrough. Clinical trials have proven that the use of SenoBright\* Contrast Enhanced Spectral Mammography has significantly improved all three.

Clinically proven results with SenoBright CESM:

- **Sensitivity:** For every 100 cancers, potentially find 13 more
- **Specificity:** 6 more benign lesions out of 100 can be correctly classified
- **Negative Predictive Value (NPV):** 19 more patients without cancer out of 100 can be sent home avoiding further anxiety/tests

GE's goal is that SenoBright will decrease the cost, improve the quality, and improve access to lifesaving diagnostic tools for breast diseases.

**\*Note:** The SenoBright option cannot be put into service until it has been made to comply with CE marking. It may not be available in all regions, and it is not cleared or approved for sale in the U.S. by the FDA.